Al chemotherapy. Re GDC-0449 Vismodegib docetaxel can be used in patients who do not show definitive evidence of disease progression during treatment with docetaxel taken into consideration before. However, currently available data to 23 evaluations.19 Phase II data from Europe Descr Nkt suggest that up to 80% of patients with docetaxel-resistant mCRPC received second-line chemotherapy, especially from clinical trials or free access programs.24 business is in Australia protected, that this number n ago at 50%, with some variations among countries. Although VER Published data from 44 Phase II studies of chemotherapy in docetaxel-resistant mCRPC, the results of many of these attempts have been disappointed; Traded. 24 There are only two Phase III randomized, controlled Lees for cytostatics in this context and SPARC25 TROPIC.14 satraplatin in the SPARC trial in patients with mCRPC were randomized to receive either satraplatin plus prednisone or placebo, and although prednisone.25 progression dir Was the siege and a more pain with satraplatin It is not give a survival advantage. Other best Tigende tests are needed before the true R Can be determined from the satraplatin in advanced prostate cancer. Cabazitaxel cabazitaxel administered iv is a semi-synthetic taxane-tubulin binding, developed by the emergence of multidrug resistance, with the existing taxanes.26 Press occur Clinical trials can k To overcome have shown that anti-tumor activity of cabazitaxel t gr he has than or equal to docetaxel, Including exist Lich activity t in cancer cells that are resistant to docetaxel.27 in the study TROPIC cabazitaxel was associated with a reduced risk of death by 30%, shipping EXTENSIONS of survival from 12.7 to 15.1 months.14 In “ENR lement in TROPIC study, patients in the group had cabazitaxel again u a median total dose of 576.6 mg/m2 of docetaxel and progression of disease at 72 % of patients experienced w during or within 3 months after the last dose of docetaxel. A total of 25% visceral metastases had, 53% had measurable disease and 46% pain had at baseline. Intentionto treat analysis of overall survival in subgroups of cabazitaxel favorable prognostic factors defined, even in patients who had progression of their disease may need during the therapy with docetaxel and those who had again U high doses, cumulative docetaxel. A post-hoc subgroup testing TROPIC shows a hnlichen proportion of patients before the docetaxel because of disease progression set. 28 In this subgroup of patients, median overall survival superior to cabazitaxel as mitoxantrone. survival advantage with cabazitaxel was also evident in patients who had prior docetaxel for reasons other than progression of the disease. This suggests that the survival advantage overmitoxantrone cabazitaxel is independent ngig of whether it was before treatment with docetaxel because of illness in Tropic progression.28 patients discontinued study was initiated at 25 mg/m2 and maintained as described by the phase of I29 and II30 data was expected, the h most frequent toxicity was t associated with Taxifolin neutropenia cabazitaxel. Grade 3 neutropenia occurred in 82% and 8% of patients developed febrile diarrhea neutropenia.14 was the hour most frequent h dermatological adverse events with cabazitaxel, with 47% of patients with diarrhea and 6.2% in the toxicity.